Protein Synthesis Inhibitors 50S- Lincosamides Flashcards
Lincosamides
- clindamycin (Dalacin®)
- chloramphenicol
- linezolid (Zyvoxam®)
clindamycin (Dalacin®)
Coverage
- GP except Enterococcus
- most community-acquired MRSA Anaerobes
clindamycin (Dalacin®)
MOA
Inhibits peptide bond formation at 50S ribosome
clindamycin (Dalacin®)
Adverse Effects
- Pseudomembranous colitis and C. difficile
- GI upset
clindamycin (Dalacin®)
Indications
- Treatment of suspected or proven infections caused by GP
- anaerobes including skin and skin structure infections
- oropharyngeal infections
- in combination with GN coverage for intra-abdominal and pelvic infections
clindamycin (Dalacin®)
Contraindications
- Hypersensitivity to clindamycin
- Infants <30 d
chloramphenicol
Coverage
GP GN Anaerobes
Chloramphenicol
MOA
Inhibits peptidyl transferase action of tRNA at 50S ribosome
chloramphenicol
Adverse Effects
- Aplastic anemia
- Grey Baby Syndrome
chloramphenicol
Indications
Serious infections by susceptible organisms when suitable alternatives are not available including meningococcal disease in patients with anaphylaxis to β-lactams
chloramphenicol
Contraindications
Hypersensitivity to chloramphenicol
linezolid (Zyvoxam®)
Coverage
GP including VRE + MRSA
linezolid (Zyvoxam®)
MOA
Binds 50S ribosome and prevents functional 70S initiation complex
linezolid (Zyvoxam®)
Adverse Effects
- HTN (acts as MAOI)
- Risks with prolonged use:
- myelosuppression
- optic neuropathy
- peripheral neuropathy
linezolid (Zyvoxam®)
Indications
- Vancomycin-resistant Enterococcus faecium infections including intra-abdominal, skin and skin structure, and urinary tract infections,
- MRSA infections as outpatient therapy
